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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Colesevelam HCl is a bile acid sequestrant (BAS) which has been speciﬁ  cally 
designed with a unique structure for the purpose of improving tolerability and reducing potential 
drug interactions compared to older BAS, such as cholestyramine and colestipol. As a class, 
BAS are known to reduce cholesterol and glucose levels, and to reduce atherosclerotic coronary 
heart disease (CHD) risk as monotherapy, and in combination with other lipid-altering drug 
therapies. Colesevelam HCl has speciﬁ  cally been shown to reduce total and low-density lipopro-
tein (LDL) cholesterol levels, and has been approved as a cholesterol-lowering drug since year 
2000. It has also been shown to reduce glucose levels. This discussion reviews mechanisms by 
which BAS lower cholesterol, and potential mechanisms by which BAS lower glucose levels 
in patients with type 2 diabetes mellitus. Finally this paper speciﬁ  cally reviews colesevelam 
HCl’s pharmacology, lipid and glucose efﬁ  cacy, safety/tolerability, and clinical use.
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Introduction
Colesevelam hydrochloride (HCl) is an orally administered, polymer, bile acid 
sequestrant (BAS) with a high capacity for binding bile acids. As a class, BAS have 
been shown to reduce low-density lipoprotein cholesterol (LDL-C) levels, variably 
increase high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels, 
reduce glucose levels, and reduce the risk of CHD (NCEP 2002). Colesevelam HCl 
has speciﬁ  cally been shown to improve hypercholesterolemia and hyperglycemia, 
which are major atherosclerotic coronary heart disease (CHD) risk factors. Reduc-
ing these CHD risk factors may account for BAS’s proven efﬁ  cacy in reducing 
CHD events.
Bile acid sequestrants: lipid and CHD efﬁ  cacy
One of the earliest CHD outcomes studies evaluating the efﬁ  cacy of lipid-altering 
drugs was the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), 
which was a study of 3806 men without CHD wherein the BAS cholestyramine was 
to be taken (by protocol) at a dose of 24 g/day; the mean duration of treatment was 
7.4 years. Overall, compared with baseline, LDL-C was reduced by 20.3% (12.6% 
compared with placebo) and HDL-C was raised by 1.6%, which was associated with 
a 19% reduction in fatal and nonfatal myocardial infarction in the BAS group (Lipid 
Research Clinics 1984a). Due to poor tolerance, and thus poor compliance to chole-
styramine, the actual amount of drug taken by study participants varied considerably 
(the average daily dose was 14 grams), allowing for an analysis which revealed that 
the dosage of cholestyramine was directly related to the degree of LDL-C lowering, Vascular Health and Risk Management 2006:2(4) 465–475
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Even though women have a higher frequency of chest pain/angina than men, the
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prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
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Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
Coronary artery disease in women: a review
on prevention, pathophysiology, diagnosis, and
treatment
A
u
t
h
o
r
 
c
o
p
y
 
o
n
l
y
Vascular Health and Risk Management 2007:3(5) 734
Bays and Jones
which in turn, was directly related to the degree of CHD risk 
reduction (Lipid Research Clinics 1984b).
Subsequent quantitative coronary angiography studies 
demonstrated that BAS, either as monotherapy or in a combi-
nation regimen, decreased progression and increased regres-
sion of atherosclerotic coronary artery lesions. A National 
Heart and Lung Blood Institute study of 116 men and women 
with CHD treated with cholestyramine 24 g/day for 5 years 
showed a 26% decrease in LDL-C and an 8% increase in 
HDL-C, with reduced atherosclerotic progression in coronary 
artery lesions with stenosis greater than 50% (Brensike et al 
1984). Both the Cholesterol Lowering Atherosclerosis Study I 
(CLAS) of 162 men with prior coronary artery bypass grafting 
treated with colestipol 30 g/day and niacin 4.3 g/day for 2 years 
(Blankenhorn et al 1987) and the CLAS II 4-year follow-up 
of a 103 men subgroup of CLAS I study participants (Cashin-
Hemphill et al 1990) revealed a LDL-C lowering of 40%–43% 
and HDL-C raising of 37%, with signiﬁ  cant decreased pro-
gression and increased regression in atherosclerotic coronary 
lesions. The Familial Atherosclerosis Treatment Study (FATS) 
evaluated 38 men with coronary artery atherosclerosis and a 
family history of cardiovascular disease treated with colestipol 
30 g/day and lovastatin 40 mg/day for 2.5 years, resulting in a 
46% decrease in LDL-C and 15% increase in HDL-C levels, 
which was associated with signiﬁ  cant decreased progression 
and increased regression of atherosclerotic coronary lesions 
compared with conventional therapy (Brown et al 1990). 
Another arm of the FATS study evaluated colestipol 30 g/day 
and niacin 4 g/day in 36 men with the same entry criteria, also 
followed for 2.5 years, and found a 32% decrease in LDL-C 
and a 43% increase in HDL-C levels. As with the FATS data 
regarding colestipol and lovastatin, colestipol and niacin was 
also associated with signiﬁ  cant decreased progression, and 
increased regression compared to conventional therapy. The 
University of California, San Francisco Specialized Center 
of Research (UCSF-SCOR) performed a study evaluating 
72 men and women with heterozygous familial hypercholes-
terolemia treated with colestipol, niacin, and lovastatin for 2 
years. LDL-C was decreased by 39%, HDL-C increased by 
26%, and the treatment group had mean regression of athero-
sclerotic coronary artery lesions, while the control group had 
mean progression (Kane et al 1990). Finally, the St. Thomas 
Arteriosclerosis Regression Study (STARS) of 90 men with 
CHD treated with cholestyramine 16 g/day for 3 years revealed 
a decrease in LDL-C by 35.7%, and increase in HDL-C by 4%, 
associated with decreased progression and increased regression 
of atherosclerotic coronary artery lesions compared to “usual 
care” therapy (Watts et al 1992).
Bile acid sequestrants: glucose 
efﬁ  cacy
In addition to improving LDL-C levels, BAS are also known 
to reduce glucose levels in patients with type 2 diabetes mel-
litus (T2DM). In a 6-week (for each period) crossover study 
of 20 men and one woman with T2DM, cholestyramine 
16 g/day decreased LDL-C by 28%, had no signiﬁ  cant 
change in HDL-C, and increased triglyceride (TG) levels   
13.5%. Fasting glucose was decreased by 13% and glycated 
hemoglobin was lowered by 0.5% (Garg and Grundy 1994). 
In a study of 70 men and women with T2DM (baseline 
HbA1c of 7.7%) treated with colestimide, 6 g/day (another 
BAS) or pravastatin 10 mg/day for 3 months, colestimide 
lowered LDL-C 23%, did not signiﬁ  cantly change HDL-
C, and increased TG by 14% (although not statistically 
signiﬁ  cant). Fasting glucose levels were decreased by 
8% and HbA1c was lowered by 0.9% (Yamakawa et al 
2007). Finally, in a pilot study of colesevelam HCl 3.75 
g/day administered to 65 men and women with T2DM on 
oral anti-diabetes drugs (OAD), LDL-C was decreased by 
11.7%, HDL-C was not signiﬁ  cantly changed, and TG were 
increased by 7.8% (which was not statistically signiﬁ  cant). 
The baseline HbA1c of 7.9% was reduced 0.5% by cole-
sevelam HCl. Fasting glucose was reduced by 14 mg/dL 
(though not statistically signiﬁ  cant), while postprandial 
glucose levels were signiﬁ  cantly decreased by 31.5% (p = 
0.026) (Zieve et al 2007).
BAS cholesterol-lowering 
mechanism of action
Bile is a green digestive and excretory ﬂ  uid and its green 
color is largely derived from hemoglobin metabolites. 
Oxygenated arterial hemoglobin pigment is normally bright 
red while deoxygenated blood in veins is blue to blue-black. 
In bruising, the pigmented hemoglobin in red blood cells is 
extravated into the dermal layers and becomes deoxygenated, 
which accounts for the initial red, blue, and purple bruise col-
ors (commonly seen within 48 hours). Afterwards, hemoglo-
bin is ingested by macrophages, and converted to bilirubin, 
which accounts for the green, yellow, and brown colors (often 
seen in bruises older than 7 days, although these times vary 
considerably) (Bariciak et al 2003). Thus, when deoxygen-
ated and chemically altered, the hemoglobin pigment may 
turn green. Chemical alternation of hemoglobin is thought 
to account for the case report ﬁ  nding of “dark green blood” 
found in a surgical patient’s arterial line, which was thought 
to be due to sulfhemoglobinemia. (It was concluded that the 
patient may have taken excessive amounts of the migraine Vascular Health and Risk Management 2006:2(4) 465–475
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incidence of obstructive CAD in the female population is lower when compared with
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addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
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medication, sumatriptan, which contains a sulfonamide group 
[Flexman et al 2007].) Because bile contains bilirubin and 
biliverdin, which are deoxygenated ﬁ  nal products of heme 
metabolism, bile has a green/yellow pigment.
From a digestive standpoint, bile contains bile acids, 
which are amphipathic (hydrophilic on one side; hydropho-
bic on the other) digestive surfactants that promote intestinal 
lipid absorption. From an excretory standpoint, bile contains 
substances that cannot be eliminated efﬁ  ciently in urine 
because they are water insoluble or protein bound. In addi-
tion to the excretion of heme metabolic products through 
biliary bilirubin, bile also contains heavy metals such as 
iron and copper, lipophilic steroids and drug metabolites 
(Hofmann 1999). Finally, bile also contains cholesterol, 
which is actively excreted by hepatocytes through the 
adenosine triphosphate binding cassette (ABC) transporter 
B 11, and accounts for approximately 2/3 of the cholesterol 
delivered to the intestine (with the other 1/3 being dietary 
cholesterol) (Bays 2002).
Bile is the predominant mechanism by which excessive 
hepatic cholesterol is excreted. Additionally, hepatocytes 
may utilize cholesterol to synthesize bile acids, which 
are then excreted into the intestine through the bile. Because 
both the biliary excretion of cholesterol and the generation of 
bile acids from hepatic cholesterol may affect hepatic LDL 
receptor activity, these metabolic processes are integral for 
maintaining cholesterol homeostasis.
The hepatic conversion of cholesterol to bile acids 
occurs through the rate-limiting enzyme, cholesterol 
cytochrome P450 7 alpha hydroxylase (CYP7A1) (Figure 1). 
Once conjugated with glycine or taurine, primary bile acids 
are then stored in the gall bladder and/or secreted into the 
intestine through the bile. Once in the intestine, bacterial 
7-dehydroxylation results in the formation of secondary 
bile acids such as lithocholic and deoxycholic acid. The 
monohydroxy lithocholic acid can undergo 7 beta-hydrox-
ylation, resulting in the formation of the tertiary, dihydroxy 
bile acid ursodeoxycholic acid. Ursodeoxycholic acid 
can undergo 7-dehydroxylation to form lithocholic acid. 
Although found in small amounts in humans, ursodeoxy-
cholic acid is the principal bile acid produced in bears. It 
may decrease the intestinal absorption of cholesterol. And 
because an imbalance in cholesterol versus bile acids may 
contribute to gallstone formation, ursodeoxycholic acid is 
therapeutically used to prevent and treat cholesterol gall-
stone formation by blocking hepatic cholesterol production, 
decreasing biliary cholesterol, and promoting the dissolu-
tion of gallstones.
Over 95% of bile acids are transported into enterocytes 
in the terminal ileum and returned to the liver via the entero-
hepatic circulation. Binding to bile acids with BAS such as 
colesevelam HCl impedes the delivery or ﬂ  ux of bile acids 
back to the liver. As the hepatic bile acid pool becomes 
diminished, CYP7A1 becomes up-regulated, increasing the 
conversion of cholesterol to bile acids, and increasing the 
activity of hydroxymethylglutaryl-coenzyme A (HMG-CoA) 
reductase (the rate-limiting step of cholesterol synthesis). The 
number of hepatic LDL receptors is also increased, which 
increases the clearance of LDL-C from the circulation, thus 
decreases LDL-C blood levels (Bays and Dujovne 2003).
BAS glucose-lowering mechanism 
of action
The mechanism of action by which BAS decrease glucose 
levels is largely unknown. Proposed mechanisms include 
alterations in luminal bile acid composition, increases in 
the incretin cholecystokinin, and effects related to hepatocyte 
nuclear factor 4 alpha (Bays and Cohen 2007).
The mechanism of action that might represent the most 
logical explanation would be the effects of BAS upon the 
nuclear receptors of farnesoid X receptors (FXR) and liver 
X receptors (LXR). Bile acids are a natural ligand for FXR, 
and activation of FXR results in repression of CYP7A1, 
thereby reducing bile acid synthesis. It is thought that FXR 
serves to protect the hepatocyte from bile acid excess, which 
can be toxic. Because BAS bind bile acids as their targeted 
mechanism of action, a decrease in enterohepatic bile acid 
availability would essentially “deactivate” or repress FXR, 
and impair hepatic FXR’s promotion of gluconeogenic genes 
such as phosphoenolpyruvate (PEPCK), a key enzyme in 
gluconeogenesis. Thus, repressed FXR activity from BAS 
may reduce PEPCK activity, reduce gluconeogensis, and 
thus lower glucose levels (Stayrook et al 2005).
But other data has not been consistent with these direct 
effects of repressed FXR activity. Another study suggests that 
FXR activation actually impairs hepatic gluconeogenic genes 
such as PEPCK (Ma et al 2006), and increases hepatic gly-
cogen synthesis, all potentially mediated through enhanced 
insulin sensitivity. Further more, activation of FXR has been 
shown to lower glucose levels in mice with diabetes mellitus 
(Zhang et al 2006). Thus, in these models, repression of FXR 
activity through BAS therapy would be expected to increase, 
not decrease, glucose levels (Zhang et al 2006).
Similarly, FXR positively regulates expression of ﬁ  bro-
blast growth factor 19 (FGF19). FGF19 normally suppresses 
CYP7A1 (Holt et al 2003), possibly as a feedback response Vascular Health and Risk Management 2006:2(4) 465–475
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to increased cellular exposure to bile acids. Additionally, 
FGF19 has been suggested to increase metabolic rate, 
decrease body weight, and improve glucose homeostasis 
(Fu et al 2004; Strack and Myers 2004). BAS decreases 
FGF19 activity, likely the result of repressed FXR activity 
(Lundasen et al 2006). Therefore, the administration of BAS 
would be expected to decrease the FXR-regulated expres-
sion of FGF19, with potential increases in glucose levels. 
This is another example suggesting that the direct effects of 
FXR repression from BAS therapy are not consistent with 
a potential to lower glucose levels, but instead are more 
consistent with a potential to raise glucose levels.
But FXR activation not only has direct effects, but also has 
important indirect effects that may affect glucose metabolism. 
As noted before, activation of FXR lowers glucose levels in 
mice with diabetes mellitus (Zhang et al 2006). This glucose 
Figure 1 Bile acid composition in bile and intestine.
Cholesterol
↓Converted by hepatic 7 α-hydroxylase
↓Converted by intestinal bacteria
1º Bile acids 
•  Chenodeoxycholic acid (Dihydroxy bile salt)
•  Cholic acid (trihydroxy bile salt)
2º Bile acids (by 7 dehydroxylation )
•  Lithocholic acid (monohydroxy bile acid) from chenodeoxycholic acid
•  Deoxycholic acid (dihydroxy bile acid) from cholic acid 
3º Bile acids 
•  Ursodeoxycholic acid (dihydroxy bile acid) (from 7 beta hydroxylation of lithocholic acid)Vascular Health and Risk Management 2006:2(4) 465–475
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1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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lowering may be the net result of the direct and indirect 
effects of FXR activation. One of the important indirect 
effects of FXR activation relates to LXR. LXR has been 
described as a “glucose sensor” (Mitro et al 2007). Among 
the glucose-related effects of LXR activity are an increase 
in insulin secretion from the pancreas (Efanov et al 2004), 
and increased adipogenesis (Seo et al 2004). An increase in 
the number of functional adipocytes, particularly in patients 
with T2DM, may improve adiposopathy, which is deﬁ  ned 
as pathogenic adipose tissue promoted by positive caloric 
balance and sedentary lifestyle in genetically and environmen-
tally susceptible patients. Adiposopathy is often characterized 
by hypertrophic visceral adipose tissue accumulation, and 
physiologically results in adverse metabolic and immune 
consequences resulting in clinical metabolic disease (Bays 
et al 2005, 2006c; Bays and Ballantyne 2006; Bays and 
Dujovne 2006; Bays 2006a). Speciﬁ  cally, increased LXR 
activity increases adipogenesis through increased expression 
of Adipocyte Determination and Differentiation-dependent 
Factor 1/Sterol Regulatory Element Binding Protein 1c, FAS 
genes, peroxisome proliferators-activated receptor gamma, 
and adipose protein 2 (Seo et al 2004).
FXR activation normally induces expression of small 
heterodimer partner (SHP), which in turn, inhibits LXR 
activity, as well as CYP7A1 (Brendel et al 2002). Repressed 
FXR activity, through the binding of bile acids with BAS, 
would be expected to decrease SHP, and release the inhibi-
tion of LXR. Thus, this indirect effect of FXR repression 
would be a relative increase in hepatic LXR activity, which 
downregulates enzymes that may contribute to hepatic 
insulin resistance and glucose intolerance. Increased 
LXR activity may also suppress hepatic gluconeogenesis, 
improve hepatic glucose utilization, and increase hepatic 
glucose uptake. Speciﬁ  cally, increased LXR activity down-
regulates 11 beta-hydroxysteroid dehydrogenase type 1 
(Stulnig et al 2002), downregules PPAR gamma, coactiva-
tor-1 alpha, and gluconeogenic enzymes such as PEPCK 
and glucose-6-phosphatase (Cao et al 2003; Lafﬁ  tte et al 
2003) and increases expression of glucokinase and GLUT-4 
(Lafﬁ  tte et al 2003).
As discussed, some of the data about FXR’s direct effects 
suggest that BAS-induced repression of FXR would increase, 
not decrease glucose levels. It may actually be that LXR is 
the dominant regulator of the glucose effect (Gupta et al 
2002). Therefore, if direct effects of FXR repression from 
BAS do indeed promote hyperglycemia, this effect may be 
overcome by the indirect increase in LXR activity, resulting 
in a net decrease in glucose levels.
Explaining some of the BAS metabolic effects through 
increased LXR activity has appeal because LXR agonists 
are known to lower glucose, lower LDL-C, and raise HDL-C 
levels (Lafﬁ  tte et al 2003; Tontonoz and Mangelsdorf 2003). 
It may be especially pertinent to note that LXR agonists have 
been shown to raise TG levels (Bays and Stein 2003). Thus, 
if increased LXR activity is an important mechanism of 
action accounting for BAS metabolic effects, then not only 
would this explain the glucose-lowering effects of BAS, but 
would also explain the variable increase in both HDL-C and 
TG levels observed with BAS (Bays and Cohen 2007) .
Several questions remain, however. For example, 
activation of CYP7A1 is one of the most fundamental 
enzyme effects of BAS treatment. Studies have shown that 
the activation of this enzyme may be only partially mediated 
by FXR (Kerr et al 2002) while other studies have suggested 
that the activation of CYP7A1 is independent of either LXR 
or FXR activity (Shibata et al 2007). This suggests that 
important metabolic effects associated with BAS therapy 
may not be signiﬁ  cantly inﬂ  uenced by either of these nuclear 
receptors. Nevertheless, while the glucose-lowering effect of 
BAS is not entirely clear, increased LXR activity from BAS 
may represent a unifying explanation as to why BAS may 
decrease glucose, increase HDL-C, and increase TG levels 
(Bays and Cohen 2007).
Colesevelam HCl pharmacology
Colesevelam HCl is hydrophilic, insoluble in water, and is 
administered orally as a solid off white tablet containing 
625 mg colesevelam HCl, which is not hydrolyzed by diges-
tive enzymes and does not undergo intestinal absorption. It 
is excreted exclusively in the feces. Colesevelam HCl may 
be administered as 6 tablets once a day, or 3 tablets twice a 
day with meals.
In a study of 16 healthy volunteers administered 
colesevelam HCl 1.9 g twice a day for 28 days, an average of 
only 0.05% of a single 14C-labeled colesevelam HCl dose 
was excreted in the urine (Welchol® Product Information 
2007) supporting its limited systemic uptake. Its structure 
is unique compared to other BAS, being a polyallylamine 
crosslinked with epichlorohydrin and alkylated with 
1-bromodecane plus 6-bromohexyltrimethylammonium 
bromide (Figure 2). This results in a more gelatinous 
consistency (and thus improved tolerability) compared with 
the more sandy-textured cholestyramine and colestipol. The 
positioning of the colesevelam HCl side chains maximizes 
interactions with bile salts, allowing for high capacity, 
speciﬁ  city, and afﬁ  nity for bile salts, and accounts for the Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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more limited potential for drug interactions (Bays and 
Dujovne 2003).
In monotherapy, the recommended starting dose is 
3 tablets twice per day with meals (including liquids) or 
6 tablets once per day with a meal (including liquids). If 
needed, colesevelam HCl may be increased to 7 625-mg 
tablets per day, although this was rarely studied in the clini-
cal trials. In combination therapy, colesevelam HCl has been 
shown to be safe and effective when used with statins, at 
doses of 4–6 tablets per day.
Colesevelam HCl cholesterol 
efﬁ  cacy studies
Early monotherapy trials demonstrated that compared 
to placebo, six 625 mg tablets colesevelam HCl per day 
decreased LDL-C by 15%–21%, increased HDL-C by 
3%–9%, and increased TG levels by 2%–16% compared 
with placebo (Bays and Dujovne 2003). Early statin 
combination trials demonstrated that compared with 
statin alone, six 625-mg colesevelam HCl tablets per day 
in combination with statins, further decreased LDL-C by 
10%–16%, increased HDL-C by 3%–7%, and increased TG 
levels by 5%–23%.
Colesevelam HCl was the ﬁ  rst BAS reported to reduce 
C-reactive protein (CRP) when added to statins (Bays et al 
2006b). A smaller study of 48 mildly hypercholesterolemic 
patients has reported that colesevelam HCl monotherapy 
lowers CRP compared with placebo, with no correlation 
to LDL cholesterol lowering (Devaraj et al 2006). It is 
possible that these ﬁ  ndings are not unique to colesevelam 
HCl, given that CRP was not routinely measured during 
the development of older BAS such cholestyramine and 
colestipol. Therefore, the lack of prior reported CRP effects 
with other BAS was likely because the data had never been 
assessed.
Colesevelam HCl has also been evaluated in combination 
with non-statin lipid-altering drugs. Colesevelam HCl 
added to ezetimibe signiﬁ  cantly reduced LDL-C by 32%, 
with non-signiﬁ  cant increases in HDL-C and TG levels 
(Bays et al 2006a), which may have clinical relevance for 
Figure 2 Comparative structure of bile acid sequestrants. Rreproduced with permission from Bays H, Dujovne C. 2003. Colesevelam HCl: a non-systemic lipid-altering 
drug. Expert Opin Pharmacother,4: 779-90. © 2003 Informa Healthcare.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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statin intolerant patients. When combined with fenoﬁ  brate, 
colesevelam HCl decreased LDL-C by 12.7% compared with 
fenoﬁ  brate monotherapy, with no statistically signiﬁ  cant 
effect on TG levels (McKenney et al 2005), which may have 
clinical relevance for hypertriglyceridemic patients with 
persistent hypercholesterolemia after ﬁ  brate therapy.
Colesevelam HCl glucose efﬁ  cacy 
studies
After the previously mentioned pilot study demonstrating that 
colesevelam HCl reduced glucose, HbA1C, and cholesterol 
levels in T2DM patients, a phase III program was initiated, 
evaluating the effects of colesevelam HCl in a larger, and 
more broad population of T2DM patients. In a 26-week 
study of 316 men and women with T2DM and treated with 
metformin monotherapy, or metformin combined with other 
OAD, colesevelam HCl six 625-mg tablets per day decreased 
LDL-C by 15.9% and increased HDL-C 0.9%, with a non-
statistically signiﬁ  cant increase in TG levels of 4.7%. The 
mean baseline HbA1c was 8.2%, and colesevelam HCl 
therapy lowered HbA1c by 0.54% and fasting glucose levels 
by 13.9 mg/dL (Bays et al 2007). In another 26-week study 
of 461 men and women with T2DM treated with sulfonylurea 
monotherapy, or combined with other OAD, colesevelam 
HCl six 625-mg tablets per day decreased LDL-C by 16.7%, 
non-statistically increased HDL-C by 0.1%, and increased TG 
levels by 17.7%. The mean baseline HbA1c was 8.2%, and 
colesevelam HCl lowered HbA1c by 0.54% and decreased 
fasting glucose levels 13.5 mg/dL (Fonseca et al 2007). 
Finally, in a 16-week study of 287 men and women with 
T2DM treated with insulin monotherapy or insulin in com-
bination with OAD, colesevelam HCl six 625-mg tablets per 
day decreased LDL-C by 12.8%, non-signiﬁ  cantly decreased 
HDL-C by 0.9%, and signiﬁ  cantly increased TG by 21.5%. 
The mean baseline HbA1c was 8.3%, and colesevelam HCl 
therapy lowered HbA1c by 0.5% and fasting glucose levels 
by 14.6 mg/dL (Goldberg and Truitt 2006). Study medication 
compliance was over 90% in both the colesevelam HCl and 
placebo groups of all three studies.
Head-to-head comparative trials of the glucose-lowering 
effects of colesevelam HCl compared with other anti-diabetes 
drug therapies have not been reported. It is perilous to com-
pare clinical trial data from different clinical trial programs, 
conducted at different time periods (sometimes decades 
apart), in patients at different stages of their disease, managed 
at different research sites, under different protocol designs, 
and with varying degrees of dietary/lifestyle intervention. 
Nonetheless, it may be of some relevance that the current 
prescribing information of sitagliptin (approved as an oral 
anti-diabetes drug therapy in 2006), reports that in T2DM 
patients with a mean baseline HbA1c of 8.0%, sitagliptin 100 
mg reduced HbA1c by 0.5%–0.7% compared with placebo 
(Januvia 2007). Thus, the HbA1c lowering of colesevelam 
HCl is in the same general range as reported with sitagliptin, 
a recently approved anti-diabetes drug. A factor that con-
tributes to reports of colesevelam HCl’s moderate HbA1c 
lowering is the protocol design, which as is more typical of 
recent anti-diabetes drug trial protocols. The entry criteria for 
HbA1c was restricted to a range of 7.5%–9.5%, with the top 
HbA1c level being lower than often found in other diabetes 
mellitus drug trials. Capping the top HbA1c entry criteria 
to lower levels blunts the mean HbA1c percent reduction 
because the higher the baseline HbA1c, the greater percent 
reduction in HbA1c with anti-diabetes drug therapies.
Drug interactions
Human drug interaction studies with colesevelam HCl have 
found no signiﬁ  cant effect on the bioavailability of digoxin, 
fenoﬁ  brate, lovastatin, metoprolol, quinidine, valproic acid, 
warfarin, or statins (Welchol® Product Information 2007). 
This is important because one of the major concerns and 
challenges with older BAS (cholestyramine and colestipol) 
was the high potential to impair the absorption of many 
common drugs, particularly anionic, acidic materials. 
Examples of concomitantly administered drugs in which 
cholestyramine has been described to potentially impair 
intestinal absorption include digitalis, diuretics, estrogens, 
hydrocortisone, penicillin G, phenobarbital, phenylbutazone, 
phosphate supplements, progesterones, propranolol, tetra-
cycline, thiazides, thyroid and thyroxine preparations, and 
warfarin (Bays and Dujovne 2003). Examples of drugs in 
which colestipol has been described to potentially impair 
intestinal absorption include digoxin (possibly), furosemide, 
gemﬁ  brozil, hydrocortisone, oral phosphate supplements, 
penicillin G, propranolol, tetracycline, and thiazide diuretics 
(Bays and Dujovne 2003). BAS may also theoretically 
interfere with fat absorption, potentially impairing absorp-
tion of fat soluble vitamins such as A, D, E, and K. Because 
of these important drug interactions, and because not all 
drugs have been evaluated for pharmacokinetic interactions, 
it is generally recommended that any concurrent drugs 
be administered at least 1 hour before, or 4 hours after 
cholestyramine or colesitpol. Colesevelam HCl has no 
such dosing requirement, with the possible exception of 
administering drugs with a narrow therapeutic index or 
margin of safety that has not been evaluated in a formal drug Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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interaction study. In this case, the concomitant drug should 
be administered at least one hour before or four hours after 
colesevelam HCl, and if available, drug blood levels should 
be monitored. A practical example is the use of colesevelam 
HCl with thyroid hormone, in that post marketing reports 
have suggested increases in thyroid stimulating hormone 
(TSH) levels in patients who have received colesevelam HCl 
co-administered with thyroid hormone replacement therapy 
(Welchol® Product Information 2007).
Safety/tolerability
Colesevelam HCl is pregnancy category B, which suggests 
that while no animal studies have demonstrated evidence of 
harm to the fetus, no adequate and well-controlled studies 
have been done in pregnant women. Thus, colesevelam HCl 
should be used during pregnancy only if clinically required. 
No special considerations, such as alteration in doses, are 
required when colesevelam HCl is administered to older 
patients. As a class, BAS are approved for use in children with 
signiﬁ  cant hypercholesterolemia (Tonstad 2000), although 
the safety and efﬁ  cacy of colesevelam HCl has not speciﬁ  -
cally been established in pediatric patients.
According to the prescribing information for colesevelam 
HCl (Welchol® Product Information, 2007), when compared 
to placebo in an integrated safety analysis, the treatment-
emergent adverse experiences that occurred in greater than 
2% did not increase with colesevelam HCl with regard 
to “Body as a Whole” or “Respiratory System”. From a 
musculoskeletal standpoint, myalgias were reported in 2% 
of colesevelam HCl administered study participants, com-
pared with 0% of those administered placebo. When adverse 
experiences relative to placebo were reported to increase with 
colesevelam HCl, they were predominantly in the digestive 
system, and included constipation (11% vs 7%) and dyspep-
sia (8% vs 3%). This is generally consistent with the clinical 
trial experience with colesevelam HCl in that the total treat-
ment-emergent adverse experiences are usually similar to 
placebo, of the same severity, with a few percentage point 
increases in the rate of constipation and dyspepsia. It should 
be noted that colesevelam HCl trials most often excluded 
study participants with major gastrointestinal abnormalities. 
Given this, colesevelam HCl is contraindicated in individuals 
with a history of bowel obstruction, and should be used with 
caution in patients with dysphagia, swallowing disorders, 
severe gastrointestinal motility disorders or major gastroin-
testinal tract surgery.
Patients with TG levels greater than 300 mg/dL were 
also excluded from colesevelam HCl clinical trials. Given 
the clinical trial evidence of a variable increase in TG with 
BAS, caution should be exercised when using any BAS in 
patients with TG levels greater than 300 mg/dL, particularly 
in patients with TG-induced pancreatitis, or otherwise at risk 
for pancreatitis.
Finally, although colesevelam HCl has not demonstrated 
reductions in vitamins A, D, E, or K during human clinical 
trials of up to one year, caution should be exercised when 
treating patients with a susceptibility to vitamin K or fat-
soluble vitamin deﬁ  ciencies.
Conclusions and place in therapy
Colesevelam HCl is indicated as an adjunct to diet and 
exercise for the reduction of elevated LDL-C in patients 
with primary hypercholesterolemia, either alone or in 
combination with statins. Although other BAS have been 
shown to reduce CHD risk, colesevelam HCl has not been 
evaluated in a CHD outcome study, and thus does not have 
an approved indication to reduce CHD risk either alone, 
or in combination with statins. However, when combined 
with a statin, colesevelam HCl has been shown to not only 
improve lipid levels (such as LDL-C and HDL-C), but also 
improve inﬂ  ammatory markers associated with increased 
CHD risk, such as CRP. The clinical use of colesevelam 
HCl is not unlike that of other lipid-altering drugs in that 
therapy should be considered as one component of an overall 
strategy of concomitant CHD risk-factor intervention. Before 
initiating therapy with colesevelam HCl, secondary causes 
of hypercholesterolemia should be evaluated and managed, 
such as poorly controlled hyperglycemia, untreated hypothy-
roidism, nephrotic syndrome, obstructive liver disease, and 
drug-induced dyslipidemias (eg, protease inhibitors, some 
immunosupressants).
Currently, 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG CoA) reductase inhibitors (“statins”) are the lipid-
altering drugs of ﬁ  rst choice for many patients towards the 
goal of decreasing LDL-C, and reducing CHD risk, because 
of the substantial clinical outcomes trial evidence and their 
demonstrated safety (Jones et al 1998; Baigent et al 2005; 
Bays 2006b, c). Recent guidelines have reduced the LDL-C 
treatment goals for patients at highest CHD risk (Grundy 
et al 2004) and have thus increased the number of high-risk 
patients who do not achieve their target levels. In other words, 
patients at highest CHD risk (Grundy et al 2004) including 
those with T2DM and CHD, are often the same patients 
who have the lowest achievement of LDL-C treatment goals 
(Davidson et al 2005; Davidson 2006). As such, statin mono-
therapy is frequently insufﬁ  cient to achieve LDL-C less than Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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70 mg/dL goals in very high CHD risk patients, especially 
when higher statin doses cannot be employed due to statin 
intolerance, safety considerations, or fear of potential adverse 
experiences (rational or otherwise) at the highest statin doses 
(Bays 2006c; Jones 2006). This has prompted a call to use 
other lipid-altering drugs in combination with statins, or 
as an alternative to statins in patients intolerant to statins. 
(Gagne et al 2002; Bays et al 2003; Bays 2004; Bays et al 
2004; Vasudevan and Jones 2006).
Since improvements in lipid levels reduce macro-
vascular CHD risk, and since improvements in glycemia 
reduce microvascular, and possibly macrovascular disease, 
patients with T2DM often receive both lipid and anti-
diabetes drugs (Bays and Cohen 2007). Colesevelam HCl 
is approved as a cholesterol-lowering drug. In December 
of 2006, the manufacturer ﬁ  led with the US Food and Drug 
Administration for approval of colesevelam HCl as a diabetes 
mellitus drug treatment. While clinical trial data is lacking as 
to whether the glucose-lowering effects of colesevelam HCl 
improves microvascular disease in patients with T2DM, if 
approved, colesevelam HCl will be the ﬁ  rst LDL-C lower-
ing medication also indicated for the glycemic treatment of 
T2DM, which may signiﬁ  cantly help T2DM patients achieve 
both their LDL-C and HbA1C goals.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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